Bio-Rad Ratings Affirmed by Fitch | GenomeWeb

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed Bio-Rad's ratings, noting the firm's stability and strong cash position but warning against continued macroeconomic headwinds.

Included in the ratings is a BBB- for Issuer Default Rating; BBB- for senior secured bank facility; BBB- for senior unsecured notes; and BB+ for senior subordinated notes.

The rating outlook for the Hercules, Calif.-based company is stable, Fitch said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.